| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
1994-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2003-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-100353639-B1 |
| titleOfInvention |
How to Induce Tolerance of Antigen-Specific T Cells |
| abstract |
The present invention relates to antibodies that bind protein gp39 (also referred to as CD40 ligand). Preferably, the antibody is a monoclonal antibody of the IgG1 isomer and binds human GP39. In a preferred embodiment, the antibody of the invention binds an epitope recognized by monoclonal antibody 24-31 produced by hybridoma 24-31 (ATCC Accession Number _____), or hybridoma 89-76 The epitopes recognized by monoclonal antibodies 89-76 produced by (ATCC Accession Number ____) are bound. The invention also relates to pharmaceutical compositions consisting of the antibodies of the invention. Antibodies of the invention are useful for inhibiting B cell proliferation and differentiation, T cell responses, and for inducing T cell resistance. Nucleic acid molecules encoding an anti-gp39 antibody or portion thereof and expression vectors and host cells incorporating said nucleic acid molecule are also encompassed by the present invention. |
| priorityDate |
1993-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |